Literature DB >> 28616715

Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study.

Masoud Soheilian1, Saeed Karimi2, Talieh Montahae1, Homayoun Nikkhah3, Seyed Aliasghar Mosavi1.   

Abstract

PURPOSE: To investigate the effects of intravitreal injection of bevacizumab (IVB) with or without anterior chamber paracentesis on intraocular pressure (IOP) and peripapillary retinal nerve fiber layer (PRNFL) thickness.
METHODS: In this prospective randomized clinical trial, 90 eyes with center involving diabetic macular edema or wet type age-related macular degeneration (AMD) were randomly assigned to receive IVB either without (group A) or with (group B) anterior chamber paracentesis. IOP was measured before and within 2 min, 30 min, 24 hours and 3 months after injections. Peripapillary spectral-domain optical coherence tomography (SD-OCT) was performed before and 3 months after injections.
RESULTS: Mean IOP changes 2 minutes, 30 minutes, 24 hours, and 3 months after injections were 26.4 ± 5.7 mmHg (P < 0.001), 6.5 ± 6.3 mmHg (P < 0.001), 0.2 ± 2.9 mmHg (P > 0.99) and 0.5 ± 2.4 mmHg (P > 0.99) in group A and -1.3 ± 2.4 mmHg (P < 0.001), -3.2 ± 1.8 mmHg (P < 0.001), -3.1 ± 1.8 mmHg (P < 0.001) and -1.8 ± 2.2 mmHg (P < 0.001) in group B, respectively Mean baseline average PRNFL thickness was 85.3±5.6 μm and 85.6 ± 5 μm in groups A and B respectively. Mean PRNFL thickness changes after 3 month was -2 ± 2 μm (P < 0.001) in group A and 0 ± 2 μm (P = 0.101) in group B. Mean PRNFL thickness in group A decreased more than group B (P < 0.001).
CONCLUSION: Conventional method of IVB injection was associated with acute IOP rise and significant PRNFL loss 3 months after injection. Anterior chamber paracentesis prevents acute IOP rise and PRNFL loss.

Entities:  

Keywords:  Bevacizumab; Intraocular pressure; Intravitreal injection; Paracentesis; Peripapillary retinal nerve fiber layer thickness

Mesh:

Substances:

Year:  2017        PMID: 28616715     DOI: 10.1007/s00417-017-3702-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  37 in total

1.  Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.

Authors:  S J Bakri; J S Pulido; C A McCannel; D O Hodge; N Diehl; J Hillemeier
Journal:  Eye (Lond)       Date:  2007-08-10       Impact factor: 3.775

2.  Reproducibility of nerve fiber layer thickness measurements using 3D fourier-domain OCT.

Authors:  Marcel N Menke; Pascal Knecht; Veit Sturm; Simeon Dabov; Jens Funk
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-01       Impact factor: 4.799

3.  Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide.

Authors:  Matthew S Benz; Thomas A Albini; Eric R Holz; Rohit R Lakhanpal; Andrew C Westfall; Mohan N Iyer; Petros E Carvounis
Journal:  Ophthalmology       Date:  2006-05-02       Impact factor: 12.079

4.  Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

Authors:  Donald J D'Amico; H N Masonson; Manju Patel; A P Adamis; E T Cunningham; D R Guyer; B Katz
Journal:  Ophthalmology       Date:  2006-04-27       Impact factor: 12.079

5.  Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.

Authors:  Quan V Hoang; Luis S Mendonca; Kara E Della Torre; Jesse J Jung; Angela J Tsuang; K Bailey Freund
Journal:  Ophthalmology       Date:  2011-11-04       Impact factor: 12.079

6.  Blood supply of the optic nerve head and its role in optic atrophy, glaucoma, and oedema of the optic disc.

Authors:  S S Hayreh
Journal:  Br J Ophthalmol       Date:  1969-11       Impact factor: 4.638

7.  Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.

Authors:  Ron A Adelman; Qi Zheng; Hylton R Mayer
Journal:  J Ocul Pharmacol Ther       Date:  2010-02       Impact factor: 2.671

8.  Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.

Authors:  Max P C Frenkel; Shamim A Haji; Ronald E P Frenkel
Journal:  Arch Ophthalmol       Date:  2010-12

9.  Persisent ocular hypertension following intravitreal ranibizumab.

Authors:  Sophie J Bakri; Colin A McCannel; Albert O Edwards; Darius M Moshfeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-19       Impact factor: 3.117

10.  The effect of acute intraocular pressure elevation on peripapillary retinal thickness, retinal nerve fiber layer thickness, and retardance.

Authors:  Brad Fortune; Hongli Yang; Nicholas G Strouthidis; Grant A Cull; Jonathan L Grimm; J Crawford Downs; Claude F Burgoyne
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-06       Impact factor: 4.799

View more
  10 in total

1.  Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF.

Authors:  M Gómez-Mariscal; B Puerto; F J Muñoz-Negrete; V de Juan; G Rebolleda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-06-28       Impact factor: 3.117

2.  Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration.

Authors:  Alicia Valverde-Megías; Aurora Ruiz-Calvo; Antonio Murciano-Cespedosa; Samuel Hernández-Ruiz; Jose María Martínez-de-la-Casa; Julián García-Feijoo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-05-03       Impact factor: 3.117

3.  Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection.

Authors:  Jocelyn Lam; Ian Luttrell; Leona Ding; Kasra Rezaei; Jennifer R Chao; Yewlin Chee; Lisa C Olmos De Koo; Joanne C Wen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-06       Impact factor: 3.117

4.  Effect of Intravitreal Injections on Retinal Imaging Metrics in Glaucomatous and Non-Glaucomatous Eyes.

Authors:  Ronaldo Nuesi; Swarup S Swaminathan
Journal:  Curr Ophthalmol Rep       Date:  2020-06-04

5.  The Effect of Acute Rises in Intraocular Pressure after Intravitreal Bevacizumab Injection on the Peripapillary Retinal Nerve Fiber Layer Thickness and the Role of Anterior Chamber Paracentesis.

Authors:  Alireza Khodabande; Mohammad Zarei; Hasan Khojasteh; Massood Mohammadi; Esmaeil Asadi Khameneh; Ali Torkashvand; Mahmood Davoodabadi
Journal:  J Curr Ophthalmol       Date:  2021-03-26

6.  Rates of RNFL Thinning in Patients with Suspected or Confirmed Glaucoma Receiving Unilateral Intravitreal Injections for Exudative AMD.

Authors:  Swarup S Swaminathan; Anne L Kunkler; Ann V Quan; Charles M Medert; Elizabeth A Vanner; William Feuer; Ta Chen Chang
Journal:  Am J Ophthalmol       Date:  2020-12-24       Impact factor: 5.488

7.  Anterior Chamber Paracentesis Offers a Less Painful Experience During Intravitreal Anti-vascular Endothelial Growth Factor Administration: An Intraindividual Study.

Authors:  Refika Hande Karakahya
Journal:  Cureus       Date:  2021-11-30

8.  Effect of Paracentesis on Retinal Function Associated With Changes in Intraocular Pressure Caused by Intravitreal Injections.

Authors:  Kazuma Kitsu; Kei Shinoda; Yoshinobu Mizuno; Kazuma Yagura; Gaku Terauchi; Celso Soiti Matsumoto; Masato Ochi; Atsushi Mizota
Journal:  Transl Vis Sci Technol       Date:  2020-08-05       Impact factor: 3.283

9.  The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis.

Authors:  Victor A de Vries; Fabiana L Bassil; Wishal D Ramdas
Journal:  Sci Rep       Date:  2020-08-06       Impact factor: 4.379

Review 10.  Intraocular Pressure Elevation Following Intravitreal Anti-VEGF Injections: Short- and Long-term Considerations.

Authors:  Ariana M Levin; Craig J Chaya; Malik Y Kahook; Barbara M Wirostko
Journal:  J Glaucoma       Date:  2021-12-01       Impact factor: 2.503

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.